Physician profile
Kelli M Danowski
NPI 1508155300
$2,962.83
in general payments reported to CMS, 2019-2025
28 companies · $546 in 2025
The $546 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $644 · 2020: $437 · 2021: $384 · 2022: $497 · 2024: $455 · 2025: $546.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $906 · Education: $94.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $906.04 |
| Education | $94.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $438.55 | 2019-2022 | |
| Almirall LLC | $410.61 | 2019-2022 | |
| Sun Pharmaceutical Industries INC. | $303.24 | 2019-2025 | |
| Abbvie INC. | $240.63 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $233.13 | 2019-2025 | Dupixent, Libtayo |
| Lilly USA, LLC | $185.65 | 2019-2025 | Taltz, Ebglyss |
| Ucb, INC. | $130.04 | 2019-2025 | Bimzelx |
| Novartis Pharmaceuticals Corporation | $119.37 | 2019-2025 | |
| Leo Pharma INC. | $100.58 | 2019-2025 | Adbry |
| Galderma Laboratories, L.P. | $100.08 | 2020-2025 | Nemluvio, Aklief |
| Incyte Corporation | $95.93 | 2024-2025 | Opzelura |
| Arcutis Biotherapeutics, INC. | $74.50 | 2024-2025 | Zoryve |
| Journey Medical Corporation | $74.38 | 2019-2022 | |
| Vyne Pharmaceuticals INC. | $69.49 | 2020-2021 | |
| Pfizer INC. | $54.82 | 2019-2020 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $49.39 | 2024 | Tremfya |
| Epi Health, LLC | $45.48 | 2019-2020 | |
| Amgen INC. | $44.71 | 2020-2025 | Otezla |
| Dermavant Sciences, INC. | $33.24 | 2024 | Vtama |
| Prugen, INC. Pharmaceuticals | $27.52 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $25.64 | 2019 | |
| Organon LLC | $18.72 | 2025 | Vtama |
| Genzyme Corporation | $17.43 | 2024 | |
| Nabriva Therapeutics, Plc | $15.46 | 2020 | |
| Encore Dermatology INC. | $14.26 | 2019 | |
| Celgene Corporation | $13.87 | 2019 | |
| Helsinn Therapeutics (U.S.), INC. | $13.11 | 2019 | |
| Glenmark Therapeutics INC. | $13.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kelli Danowski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.